期刊
CLINICAL IMMUNOLOGY
卷 138, 期 2, 页码 187-200出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2010.11.006
关键词
S. Typhi; Prime-boost immunization; Vi capsular polysaccharide; CVD 909; B memory; Vaccine Ty21a
类别
资金
- NIAID, NIH, DHHS [N01 AI30028, N01-AI65299, R01-AI036525, U19 AI082655, R01-AI065760, M01-6616500]
Attenuated live oral typhoid vaccine candidate CVD 909 constitutively expresses Salmonella Typhi capsular polysaccharide antigen (Vi). A randomized, double-blind, heterologous prime-boost clinical study was conducted to determine whether immunity to licensed parenteral Vi vaccine could be enhanced by priming with CVD 909. Priming with CVD 909 elicited higher and persistent, albeit not significant, anti-Vi IgG and IgA following immunization with Vi, than placebo-primed recipients. Vi-specific IgA B memory (B-M) cells were significantly increased in CVD 909-primed subjects. S. Typhi-specific LPS and flagella IgA B-M cells were observed in subjects immunized with CVD 909 or with the licensed Vi-negative oral typhoid vaccine Ty21a. CVD 909-induced B-M cells exhibited a classical B-M phenotype (i.e., CD3(-)CD19(+)IgD(-)CD27(+)). This is the first demonstration of classical B-M cells specific for bacterial polysaccharide or protein antigens following typhoid immunization. The persistent IgA B-M responses demonstrate the capacity of oral typhoid vaccines to prime mucosally relevant immune memory. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据